Abstract:Fundamentally, cancer arises from genetic and epigenetic alterations that interplay to reprogram gene expression networks, leading to unrestrained proliferation. Glioblastoma (GBM) is the most prevalent and aggressive primary brain cancer, with a median survival of approximately one year and a 5-year survival rate of just 5%. The standard care for GBM patients has remained unchanged for decades, underscoring the need for a better understanding of GBM biology to develop more effective therapies. The relatively low genetic mutation burden in GBM highlights the significant role of epigenetic mechanisms in its pathogenesis. Our recent work shows that chromatin remodeling plays pivotal roles in GBM pathogenesis. The BRD8-driven EP400 chromatin remodeling complex maintains GBM by crippling p53-mediated tumor suppression in an unprecedented way through hijacking the histone variant H2AZ at p53 target loci, enforcing a repressive chromatin state that prevents p53-mediated transactivation. Targeting BRD8 in TP53 WT GBM, which makes up ~71% of all GBM cases, enhances chromatin accessibility by evicting H2AZ. This restores p53-mediated transactivation of its targets, reestablishes cell cycle arrest, inhibits gliomagenesis, and prolongs survival in xenograft models of TP53 WT GBM. Conversely, the NuRD chromatin remodeling complex driven by CHD5 governs the MYC-mediated oncogenic network to prevent gliomagenesis. Mechanistically, CHD5 forms a CHD3-containing but CHD4-independent NuRD complex that directly binds to the MYC promoter and super enhancers. Chd5 loss triggers the remodeling of chromatin, enhances chromatin accessibility at Myc loci, augments Myc expression, significantly impairs NSCs differentiation while promotes proliferation, transformation, and gliomagenesis in vivo . Furthermore, reactivating CHD5 in human GBM xenograft models significantly extends survival. Thus, our findings reveal previously unappreciated epigenetic mechanisms by which GBM cells reprogram both tumor-suppressive and oncogenic transcription networks to facilitate their outgrowth. This sheds new light on our understanding of GBM malignancy and provides promising therapeutic opportunities for treating patients with this devastating malignancy.

C/EBPβ Mediates NQO1 and GSTP1 Anti-Oxidative Reductases Expression in Glioblastoma, Promoting Brain Tumor Proliferation

NQO1 Drives Glioblastoma Cell Aggressiveness Through EMT Induction Via the PI3K/Akt/mTOR/Snail Pathway

Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma

Antioxidant network-based signatures cluster glioblastoma into distinct redox-resistant phenotypes

SREBP2/Rab11s/GLUT1/6 Network Regulates Proliferation and Migration of Glioblastoma

Knockdown of NF-E2-related Factor 2 Inhibits the Proliferation and Growth of U251MG Human Glioma Cells in a Mouse Xenograft Model

EGFR Activates GDH1 Transcription to Promote Glutamine Metabolism Through MEK/ERK/ELK1 Pathway in Glioblastoma.

NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation

Nuclear Translocation of LDHA Promotes the Catabolism of BCAAs to Sustain GBM Cell Proliferation through the TxN Antioxidant Pathway

SREBP2/Rab11s/GLUT1/6 network regulates proliferation and migration of glioblastoma.

The Regulation of ROS- and BECN1-Mediated Autophagy by Human Telomerase Reverse Transcriptase in Glioblastoma

GSH Depletion and Consequent AKT Inhibition Contribute to the Nrf2 Knockdown-Induced Decrease in Proliferation in Glioblastoma U251 Cells.

Epco-27. Chromatin Remodeling Reprograms The Transcription Network In Glioblastoma

EGFR‐ERK pathway regulates CSN6 to contribute to PD‐L1 expression in glioblastoma

The Significance of the Redox Gene in the Prognosis and Therapeutic Response of Glioma

The mechanism of extracellular CypB promotes glioblastoma adaptation to glutamine deprivation microenvironment

NRBP1 promotes malignant phenotypes of glioblastoma by regulating PI3K/Akt activation

EGFRvIII Promotes the Proneural-Mesenchymal Transition of Glioblastoma Multiforme and Reduces Its Sensitivity to Temozolomide by Regulating the NF-?B/ALDH1A3 Axis

Molecular Characterization of AEBP1 at Transcriptional Level in Glioma

Upregulation of DNA Metabolism-Related Genes Contributes to Radioresistance of Glioblastoma.

Tumor grade related expression of neuroglobin is negatively regulated by PPARγ and confers antioxidant activity in glioma progression